Literature DB >> 32572772

Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.

J Stephen Mikita1, Jules Mitchel2, Nicolle M Gatto3, John Laschinger4, James E Tcheng5, Emily P Zeitler5, Arlene S Swern6, E Dawn Flick6, Christopher Dowd7, Theodore Lystig8, Sara B Calvert9.   

Abstract

BACKGROUND: Patient registries are organized systems that use observational methods to collect uniform data on specified outcomes in a population defined by a particular disease, condition, or exposure. Data collected in registries often coincide with data that could support clinical trials. Integrating clinical trials within registries to create registry-embedded clinical trials offers opportunities to reduce duplicative data collection, identify and recruit patients more efficiently, decrease time to database lock, accelerate time to regulatory decision-making, and reduce clinical trial costs. This article describes a project of the Clinical Trials Transformation Initiative (CTTI) intended to help clinical trials researchers determine when a registry could potentially serve as the platform for the conduct of a clinical trial.
METHODS: Through a review of registry-embedded clinical trials and commentaries, semi-structured interviews with experts, and a multi-stakeholder expert meeting, the project team addressed how to identify and describe essential registry characteristics, practices, and processes required to for conducting embedded clinical trials intended for regulatory submissions in the United States.
RESULTS: Recommendations, suggested practices, and decision trees that facilitate the assessment of whether a registry is suitable for embedding clinical trials were developed, as well as considerations for the design of new registries. Essential registry characteristics include relevancy, robustness, reliability, and assurance of patient protections.
CONCLUSIONS: The project identifies a clear role for registries in creating a sustainable and reusable infrastructure to conduct clinical trials. Adoption of these recommendations will facilitate the ability to perform high-quality and efficient prospective registry-based clinical trials.

Entities:  

Keywords:  Clinical trials; Methodology; Multi-stakeholder; Randomized registry trials; Registry-embedded clinical trials

Mesh:

Year:  2020        PMID: 32572772      PMCID: PMC7785536          DOI: 10.1007/s43441-020-00185-5

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  43 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  The use of a registry database in clinical trial design: assessing the influence of entry criteria on statistical power and number of eligible patients.

Authors:  Linda Peelen; Niels Peek; Evert de Jonge; Gert Jan Scheffer; Nicolette F de Keizer
Journal:  Int J Med Inform       Date:  2006-07-07       Impact factor: 4.046

3.  Expanding the evidence base in transplantation: more and better randomized trials, and extending the value of observational data.

Authors:  Jonathan C Craig; Angela C Webster; Andrew Mitchell; Les Irwig
Journal:  Transplantation       Date:  2008-07-15       Impact factor: 4.939

Review 4.  The cost of drug development: a systematic review.

Authors:  Steve Morgan; Paul Grootendorst; Joel Lexchin; Colleen Cunningham; Devon Greyson
Journal:  Health Policy       Date:  2011-01-21       Impact factor: 2.980

5.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.

Authors:  Jacqueline Corrigan-Curay; Leonard Sacks; Janet Woodcock
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

6.  A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.

Authors:  Sunil V Rao; Connie N Hess; Britt Barham; Laura H Aberle; Kevin J Anstrom; Tejan B Patel; Jesse P Jorgensen; Ernest L Mazzaferri; Sanjit S Jolly; Alice Jacobs; L Kristin Newby; C Michael Gibson; David F Kong; Roxana Mehran; Ron Waksman; Ian C Gilchrist; Brian J McCourt; John C Messenger; Eric D Peterson; Robert A Harrington; Mitchell W Krucoff
Journal:  JACC Cardiovasc Interv       Date:  2014-08       Impact factor: 11.195

7.  Bleeding avoidance strategies. Consensus and controversy.

Authors:  Harold L Dauerman; Sunil V Rao; Frederic S Resnic; Robert J Applegate
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

8.  Use of health plan combined with registry data to predict clinical trial recruitment.

Authors:  Jeffrey R Curtis; Nicole C Wright; Fenglong Xie; Lang Chen; Jie Zhang; Kenneth G Saag; Aseem Bharat; Joel Kremer; Stacey Cofield; Kevin Winthrop; Elizabeth Delzell
Journal:  Clin Trials       Date:  2013-12-17       Impact factor: 2.486

9.  Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry.

Authors:  Bina Ahmed; Winthrop D Piper; David Malenka; Peter VerLee; John Robb; Thomas Ryan; Michael Herne; William Phillips; Harold L Dauerman
Journal:  Circ Cardiovasc Interv       Date:  2009-09-01       Impact factor: 6.546

10.  Integrating cancer survivors' experiences into UK cancer registries: design and development of the ePOCS system (electronic Patient-reported Outcomes from Cancer Survivors).

Authors:  L Ashley; H Jones; J Thomas; D Forman; A Newsham; E Morris; O Johnson; G Velikova; P Wright
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

View more
  2 in total

1.  Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development.

Authors:  Cornelia Henschke; Dimitra Panteli; Marie Dreger; Helene Eckhardt; Susanne Felgner; Hanna Ermann; Hendrikje Lantzsch; Tanja Rombey; Reinhard Busse
Journal:  Implement Sci       Date:  2021-10-30       Impact factor: 7.327

2.  Real World Evidence in Medical Cannabis Research.

Authors:  Rishi Banerjee; Simon Erridge; Oliver Salazar; Nagina Mangal; Daniel Couch; Barbara Pacchetti; Mikael Hans Sodergren
Journal:  Ther Innov Regul Sci       Date:  2021-11-08       Impact factor: 1.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.